Relizorb— 510(k) K163057

Substantially Equivalent

Alcresta Therapeutics, Inc.

FDA 510(k) clearance K163057 for Relizorb, Substantially Equivalent on 2017-07-12. Applicant: Alcresta Therapeutics, Inc..

Clearance details

Applicant: Alcresta Therapeutics, Inc.
Product code: Code PLQ
Advisory panel: Gastroenterology, Urology
Date received: 2016-11-01
Decision date: 2017-07-12
Decision: Substantially Equivalent
Clearance type: Traditional
Location: Newton, MA, US

Download summary PDF View on FDA.gov ↗

Data sourced from openFDA. This site is unofficial and independent of the FDA.